(S)-2-(1-(9H-purin-6-ylamino)ethyl)-6-bromo-3-phenyl-4H-chromen-4-one | 1300583-13-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: (S)-2-(1-(9H-purin-6-ylamino)ethyl)-6-bromo-3-phenyl-4H-chromen-4-one
• 英文别名: 6-bromo-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)ethyl]chromen-4-one
• CAS: 1300583-13-4
• 化学式: C₂₂H₁₆BrN₅O₂
• 分子量: 462.305
• InChiKey: CCDVYDSKPOSJQL-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  92.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-(5-溴-2-羟基苯基)-2-苯基乙酮 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 二氯甲烷 、 叔丁醇 为溶剂， 反应 38.0h， 生成 (S)-2-(1-(9H-purin-6-ylamino)ethyl)-6-bromo-3-phenyl-4H-chromen-4-one
  参考文献：
  名称：

  NOVEL KINASE MODULATORS

  摘要：

  本发明提供了PI3K蛋白激酶调节剂，其制备方法，含有它们的药物组合物，以及使用它们进行激酶介导的疾病或紊乱的治疗、预防和/或改善的方法。

  公开号：

  US20110118257A1

文献信息

• NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROMEN-4-ONE DERIVATIVES AND THEIR USE IN PREPARING PHARMACEUTICALS
  申请人：Rhizen Pharmaceutical SA

  公开号：US20150087699A1

  公开（公告）日：2015-03-26

  The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.

  本发明涉及作为药物中间体有用的化合物，用于制备中间体的过程，用于这些过程中使用的中间体，以及在制备药物中使用这些中间体。具体来说，本发明涉及对映纯的可选取代的2-(1-羟基-烷基)-香豆素衍生物，其表示为式（IA）和（IB），制备醇衍生物的过程以及它们在制备药物中的使用。
• Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
  申请人：Rhizen Pharmaceuticals SA

  公开号：US09309216B2

  公开（公告）日：2016-04-12

  The present invention relates to compounds useful as pharmaceutical intermediates, to processes for preparing the intermediates, to intermediates used in the processes, and to the use of the intermediates in the preparation of pharmaceuticals. In particular, the present invention concerns enantiomerically pure optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives represented by formula (IA) and (IB), processes for preparing the alcohol derivatives and their use in preparing pharmaceuticals.

  本发明涉及化合物，其作为制药中间体有用，涉及制备该中间体的过程，涉及用于该过程的中间体，以及用于制备制药品的中间体。特别地，本发明涉及对映纯的可选取代的2-(1-羟基-烷基)-香豆素衍生物，其由公式（IA）和（IB）表示，制备醇衍生物的过程以及它们在制备制药品中的应用。
• KINASE MODULATORS
  申请人：Rhizen Pharmaceuticals S.A.

  公开号：EP3050876A2

  公开（公告）日：2016-08-03

  The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

  本发明提供了 PI3K 蛋白激酶调节剂、制备方法、含有这些调节剂的药物组合物以及用它们治疗、预防和/或改善激酶介导的疾病或紊乱的方法。
• Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
  申请人：Rhizen Pharmaceuticals SA

  公开号：US10058539B2

  公开（公告）日：2018-08-28

  This present invention relates to a method of treating a autoimmune, respiratory and/or inflammatory disease or condition (e.g., psoriasis, rheumatoid arthritis, asthma, COPD). The method comprises administering a PI3K Delta inhibitor or a dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor. The present invention also relates to pharmaceutical compositions containing a PI3K Delta or dual PI3K Delta-Gamma inhibitor and a PDE4 inhibitor.

  本发明涉及一种治疗自身免疫性、呼吸道和/或炎症性疾病或病症（如银屑病、类风湿性关节炎、哮喘、慢性阻塞性肺病）的方法。该方法包括给药 PI3K Delta 抑制剂或双重 PI3K Delta-Gamma 抑制剂和 PDE4 抑制剂。本发明还涉及含有PI3K Delta或双重PI3K Delta-Gamma抑制剂和PDE4抑制剂的药物组合物。
• 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases
  申请人：Muthuppalaniappan Meyyappan

  公开号：US10442783B2

  公开（公告）日：2019-10-15

  The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

  本发明提供了 PI3K 蛋白激酶调节剂、制备方法、含有这些调节剂的药物组合物以及用它们治疗、预防和/或改善激酶介导的疾病或紊乱的方法。